ASH 2010 ICT with DFX in Transfusion Dependent MDS
 

2928 Iron Chelation Therapy with Deferasirox In Transfusion Dependent Myelodysplastic Syndrome Patients. Preliminary Report From the Prospective MDS0306 GIMEMA Trial

http://ash.confex.com/ash/2010/webpr...aper32194.html

"Patients started treatment with the standard 20 mg/kg Deferasirox dose but dose adjustments on clinical indications were allowed." The duration of the treatment was 1 year.

"61 patients (49%) prematurely interrupted the study (drop out), 62 (51%) patients completed the planned year of treatment."

Discussion: "Preliminary results from the GIMEMA MDS0306 study confirmed feasibility of Deferasirox therapy in transfusion dependent MDS patients. Drop out rate, toxicity related drop out and severe side effects were similar to those reported in other trials even if the present population presented clinical characteristics of more advanced disease and age. The rate of progression is coherent with prolonged disease story. Serum ferritin behavior confirms Deferasirox efficacy. The serum ferritin reduction was more evident in the more heavily overloaded population indicating successful iron depletion in this group of patients as clinically requested."